| Document |
Document Title |
|
WO/2012/024893 |
Chemical entities which are triterpenoid derivatives, pharmaceutical compositions and methods of treatment of inflammatory, neurodegenerative, neoplastic and autoimmune diseases are described.
|
|
WO/2012/022780 |
The invention relates to the medical and cosmetic field, more precisely the field of anticancer treatment and treatment of inflammatory diseases and diabetes and the field of anti-aging or anti-wrinkling agents using newly synthesized 18...
|
|
WO/2012/020021 |
The present invention encompasses compounds of general formula (I) wherein R3a to R31 and X are defined as in claim 1, which are suitable for the treatment of and/or prevention of chronic inflammatory diseases, autoimmune diseases, skin ...
|
|
WO/2012/020021 |
The present invention encompasses compounds of general formula (I) wherein R3a to R31 and X are defined as in claim 1, which are suitable for the treatment of and/or prevention of chronic inflammatory diseases, autoimmune diseases, skin ...
|
|
WO/2012/006864 |
Disclosed are a series of pentacyclic triterpenoid compounds, preparation methods and uses thereof. The compounds have anti-inflammatory, anti-tumor, anti-bacterial and antiviral activities, and they can be used for treating urinary inco...
|
|
WO/2011/153319 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 and C-28 betulinic acid derivatives that possess unique antiviral activity are provided a...
|
|
WO/2011/153315 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 betulinic acid and other structurally related natural products derivatives that possess u...
|
|
WO/2011/138460 |
The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.
|
|
WO/2011/074608 |
Disclosed is a prophylactic or therapeutic agent for chronic hepatitis C, which contains a triterpene derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. (In formula (I), R...
|
|
WO/2011/074607 |
Disclosed is a triterpene derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed is a prophylactic or therapeutic agent for chronic hepatitis C, which contains the above-described trit...
|
|
WO/2011/007230 |
The invention relates to novel lupeol-type triterpene derivatives and related compounds, and pharmaceutical compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.
|
|
WO/2011/007230 |
The invention relates to novel lupeol-type triterpene derivatives and related compounds, and pharmaceutical compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.
|
|
WO/2010/139253 |
A compound represented by formula II, a preparation method and uses thereof in treating liver damage, inflammation and so on are disclosed. A method for preparing glycyrrhetinic acid derivatives are also disclosed. In the compound repres...
|
|
WO/2010/103046 |
The present invention encompasses novel triterpene compounds of general formula I, wherein R3a, R3b, R11a, R11 b, R31 and R32 are defined as in claim 1, which are suitable for the prevention and/or treatment of diseases mediated by 11 β...
|
|
WO/2010/054606 |
The invention describes novel triterpenoid 2-deoxy glycosides of general formula I, wherein at least one of the substituents X1 and R2 contains a 2-deoxy glycosidic group, method of preparation thereof, their cytotoxic activity and a pha...
|
|
WO/2010/054606 |
The invention describes novel triterpenoid 2-deoxy glycosides of general formula I, wherein at least one of the substituents X1 and R2 contains a 2-deoxy glycosidic group, method of preparation thereof, their cytotoxic activity and a pha...
|
|
WO/2010/044371 |
A sweet taste receptor agonist such as acesulfame K, sucralose, saccharin or glycyrrhizin can be used as an active ingredient for an insulin secretion stimulator. A candidate substance for an insulin secretion stimulator can be screened...
|
|
WO/2010/032123 |
The present invention provides therapeutically active compounds and compositions as receptor antagonists and methods of use thereof. In one aspect, the compounds are useful in modulating pain, inflammation and acute phase reactions by in...
|
|
WO/2010/029915 |
Disclosed is a simple method for producing a plant containing sapogenin, which contains a large quantity of sapogenin and has outstanding taste and safety, using a plant containing saponin as the raw material. The method for producing a ...
|
|
WO/2010/007788 |
Disclosed is a gap junction inhibitor which is more practically useful compared with carbenoxolone. Also disclosed is a novel glycyrrhetinic acid derivative. The glycyrrhetinic acid derivative is represented by general formula (1) or (2).
|
|
WO/2009/151035 |
Disclosed is a therapeutic agent for overactive bladder, which comprises a glycyrrhetinic acid component or a pharmaceutically acceptable salt thereof. The therapeutic agent is particularly effective on myogenic overactive bladder or ov...
|
|
WO/2009/146619 |
A method for producing betulinic acid uses betulin as the starting material and comprises the following steps: (1) betulin is oxidized to prepare betulin aldehyde crude product; (2) betulin aldehyde crude product is oxidized to obtain be...
|
|
WO/2009/146216 |
Disclosed herein are novel oleanolic acid derivatives. Methods of preparing these compounds are also disclosed. The oleanolic acid derivatives of this invention may be used for the treatment and prevention of many diseases, including can...
|
|
WO/2009/146216 |
Disclosed herein are novel oleanolic acid derivatives. Methods of preparing these compounds are also disclosed. The oleanolic acid derivatives of this invention may be used for the treatment and prevention of many diseases, including can...
|
|
WO/2009/135352 |
A plum tree extract comprises 0.5-50 wt% squalene The plum tree extract mainly comes from fat-soluble portion and/or water-soluble portion of non-fruit part of plum tree A method for preparing the plum tree extract, comprises using super...
|
|
WO/2009/129545 |
This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising suc...
|
|
WO/2009/129546 |
This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising suc...
|
|
WO/2009/129548 |
This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising ...
|
|
WO/2009/129545 |
This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising suc...
|
|
WO/2009/117987 |
The present invention relates to new boswellia acid derivatives. The present invention furthermore relates to the use of preparations with boswellia acid derivatives or synthetic derivatives, especially with boswellia acid derivatives, w...
|
|
WO/2009/117987 |
The present invention relates to new boswellia acid derivatives. The present invention furthermore relates to the use of preparations with boswellia acid derivatives or synthetic derivatives, especially with boswellia acid derivatives, w...
|
|
WO/2009/100532 |
The invention relates to 17ß lupane derivatives of formula (I): wherein R1 and X are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the inventi...
|
|
WO/2009/094958 |
This invention relates to saccharide lupane derivatives of general formula (I), wherein R denotes substituent independently selected from the group comprising hydrogen, hydroxy, amino, mercapto, alkyloxy, alkyl and saccharide group, R´ ...
|
|
WO/2009/082818 |
The invention relates to 21 -keto triterpene compounds of formula (I): wherein R1, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/082818 |
The invention relates to 21 -keto triterpene compounds of formula (I): wherein R1, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/082819 |
The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/082819 |
The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/072916 |
Friedelin is a natural compound with promising proprieties. On its own or with chemical modification it is possible to introduce relevant biological activities, e. g., anti-cancer, anti-aging and agrochemical. Its availability in signifi...
|
|
WO/2009/067891 |
The invention discloses water-soluble triterpenephenol compounds having antitumor activity represented by formula (I), wherein the substituents R1-R4 and M are defined as in the description. The invention also discloses a method for prep...
|
|
WO/2009/060601 |
Disclosed is a novel derivative having remarkable curative effects on malignant tumors, for which a natural triterpene compound serves as a lead compound. Specifically disclosed is an agent for treatment of malignant tumors, which contai...
|
|
WO/2008/155890 |
It is intended to provide a method for producing aglycone from a glycoside efficiently at low cost without using an acid catalyst or an organic solvent. The method for producing glycoside aglycone, characterized by bringing a glycoside i...
|
|
WO/2008/138200 |
The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in preventing and treating central nervous system disorders by inhibiting over-activation of NMDA and/...
|
|
WO/2008/140345 |
The invention relates to biologically active agents, in particular to glycyrrhizic acid derivatives, and also to substances for inhibiting the reproduction of human immunodeficiency virus. Glycyrrhizic acid di- and/or trinicotinates of g...
|
|
WO/2008/136838 |
The invention concerns novel synthetic triterpenoids, such as CDDO-EA and CDDO-TFEA, and their use for the treatment and prevention of diseases, such as MS.
|
|
WO/2008/137599 |
Novel 2-alkoxyestradiol analogs, pharmaceutical compositions and methods of treatment of proliferative and angiogenesis associated conditions are disclosed.
|
|
WO/2008/124922 |
Compounds having the structure, their salts or N-oxide derivatives: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, a...
|
|
WO/2008/111497 |
Disclosed is a novel prophylactic or therapeutic agent for an ophthalmic disease associated with oxidative stress. A compound represented by the general formula (I) or a salt thereof has an excellent activity of inducing the phase-II enz...
|
|
WO/2008/086759 |
The invention relates to a method of preparation and isolation of betulin diacetate from birch bark from paper mills and its optional processing to betulin, wherein the birch bark is ground, mixed with two- to twenty-fold excess volume o...
|
|
WO/2008/086759 |
The invention relates to a method of preparation and isolation of betulin diacetate from birch bark from paper mills and its optional processing to betulin, wherein the birch bark is ground, mixed with two- to twenty-fold excess volume o...
|
|
WO/2008/083461 |
There is provided a method of producing a plant composition comprising dehydrosoyasaponin I (D-I), the method comprising the steps of extracting a plant flour with a solvent capable of extracting soyasaponins to produce an extract, and t...
|
